You are here: Industry Insights > Biopharma

News List

How Blockchain Might be Used by Biopharma to Trade Data biospace
April 08, 2018
Blockchain is best known—if it’s known at all—as being linked to the cryptocurrency Bitcoin
Top Trends Impacting Biopharma Innovation Strategy in 2018 biospace
January 25, 2018
The biopharma industry is perceived to be at a turning point, where companies have the opportunity to meaningfully adapt their innovation strategy and take advantage of major technological advances and new therapeutic modalities.
5 Worthwhile M&A Targets for 2018 biospace
January 16, 2018
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Biopharma trends to watch in 2018 biopharmadive
December 27, 2017
The drug pricing debate will likely stay in the headlines in the new year, while M&A could get a jumpstart after Congress passed a new tax law that could make deals more lucrative.
Cue Biopharma announces research collaboration with Merck biospectrumasia
November 20, 2017
Under the terms of the deal, the CUE Biologics™ platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets for the treatment of autoimmune disease
Cryoport revenue up 52%; driven by bioPharma biospectrumasia
November 07, 2017
Biopharma revenue up 65% year-over-year; 23 new clinical trials added during third quarter.
Biopharma intelligence firm launches integrated clinical trial database fiercebiotech
September 15, 2017
New Jersey-based biopharma intelligence firm Ozmosi has launched GlobalClinicalTrialsData.com, with the ambition to provide information on almost all clinical trials around the world through a single platform.
MiMedx to divest Stability Biologics business to focus on biopharma pharmaceutical-technology
August 23, 2017
MiMedx Group has signed a new definitive agreement with former stockholders of Stability to sell its subsidiary, Stability Biologics, back to the stockholders to focus on biopharma.
Could a Trump-mandated cash repatriation spur pharma M&A, or just share buybacks? fiercepharma
August 11, 2017
Pfizer made one big deal after the last tax holiday on repatriated cash, and it could do so again if Trump makes good on tax-reform vows.
Biopharma stages a strong recovery over the first half even as M&A deals disappoint cphi-online
August 07, 2017
EP Vantage releases half-year reviews of pharma & biotech and medtech performance.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page